Gastroenterology

Preliminary study results showed that Fecal donor-unrelated donor mix for initial Clostridium difficile infection is associated with specific bacterial communities that do not resemble the donors’ sample.

The NeoTract product was originally indicated to treat those with BPH aged 50 years and older.

The first patients have been enrolled into the first-in-human IMM-529 clinical study for the treatment of Clostridium difficile infection.

The study highlights potential racial and medical characteristics that affect the access of the patients to FMT.

The novel solution is being investigated for patient acceptability and compliance to bowel cleansing.

Reducing delays can help stop the spread of the infection and initiate treatment to patients quickly.

Complementary and alternative medicine can decrease the rate of antimicrobial resistance and reduce treatment costs.

Implementing a standardized C. difficile screening protocol was associated with a significant decrease in the rate of HO-CDI among BMT patients

The approval has expanded ferumoxytol's indication to include all adults with iron deficiency anemia.

While maintaining contact precautions for extended periods can keep from spreading, unnecessarily long isolation can negatively impact care.

Trulance is the only treatment thought to replicate the pH-sensitive activity of uroguanylin.

Data showed that 30-day mortality rates were significantly lower in CIU patients (18.8%) in comparison to original bed patients (34%).

The first participant has been enrolled in the American Gastroenterological Association’s (AGA) FMT study, planned to be the largest of its kind.

Drossman explains why he thinks the field of research for irritable bowel syndrome is "wide open" for clinicians.

The Professor Emeritus, Medicine and Psychiatry, University of North Carolina School of Medicine, explains the distinct and strengthened connection between the brain and the gut.

Reddit's Ask Me Anything forums have proven to give physicians a chance to connect with and educate thousands of people at once.

The FDA made its decision based on data from a phase 3 trial including more than 200 patients.

Broad spectrum antibiotics may be to blame for healthcare facility-onset CDI.

The FDA Data Monitoring Committee recommended Celgene discontinue the mongersen trials.